Tag Archives: In Vitro Diagnostic Reagents

Admission Approval / 准入审批, Healthcare & Pharma / 医药医疗

Medical Device GMP: How the Four New Inspection Principles Judge Conformity

  • China’s revised Medical Device GMP took effect on 1 November 2026, together with four supporting inspection principles issued by the NMPA on 23 October 2026.
    新修订的《医疗器械生产质量管理规范》自 2026 年 11 月 1 日起施行，国家药监局已于 2026 年 10 月 23 日印发四个配套检查指导原则。
  • The principles cover Sterile Devices, implantable devices, In Vitro Diagnostic Reagents and customised dentures, replacing the 2015 and 2016 on-site principles on the same date.
    四个指导原则覆盖无菌医疗器械、植入性医疗器械、体外诊断试剂和定制式义齿，并于同日废止 2015 年、2016 年的现场检查指导原则。
  • From 1 November 2026, production licence verification and post-market supervision inspections for these four families are judged against the new principles.
    自 2026 年 11 月 1 日起，这四类产品的生产许可核查与上市后监督检查，均按新指导原则进行结果判定。
  • Inspection items are graded into Critical Items, major items and general items by each clause’s importance in the quality system and the risk its non-compliance creates.
    检查项目按各条款在质量管理体系中的重要性及不符合带来的风险，划分为关键项目、主要项目、一般项目三个等级。
  • The principles merge the GMP with its annexes and convert the combined text into inspection items, so the annex is no longer read on its own.
    指导原则是把规范与相应附录融合衔接、转化形成检查项目，附录不再作为单独文本另行对照。
  • A failed Critical Item normally means the inspection fails outright, but that is settled inspection practice rather than a rule written into these documents.
    关键项目不合格通常直接判定不通过，但这是检查实务的通行做法，不是这四份文件写明的条文。
  • New applicants and long-held licence holders are measured on the same new scale, so gap analysis cannot wait for the next renewal.
    新办证与老持证企业适用同一把新尺子，差距分析不能等到下一次换证。

Medical Device GMP: How the Four New Inspection Principles Judge Conformity | 医疗器械 GMP：四个新检查指导原则如何判定符合性

Overview

On 23 October 2026 the National Medical Products Administration issued four inspection principles to accompany the revised Medical Device Good Manufacturing Practice, which takes effect on 1 November 2026. The four cover sterile medical devices, implantable medical devices, in vitro diagnostic reagents and customised dentures, and they take effect on the same day as the revised GMP.

The notice also repeals what came before: the 2015 on-site inspection principles for sterile, implantable and IVD production (Shi Yao Jian Xie Jian [2015] No. 218) and the 2016 principles for customised dentures (Shi Yao Jian Xie Jian [2016] No. 165).

Why the annexes were folded in

The drafting method is stated plainly. Each principle takes the GMP and the corresponding annex — sterile, implantable and so on — merges them, and converts the combined text into inspection items. The annex stops being a separate document read beside the GMP; it becomes part of the checklist.

That changes how a quality team holds its documentation. A system that mapped its procedures to the GMP and treated the annex as a second layer now has one layer, and the mapping must be rebuilt rather than relabelled.

Who is measured on the new scale

Four product families: sterile devices, implantable devices, IVD reagents and customised dentures. Both production licence verification — new applications and scope changes — and post-market supervision inspections use the new principles to determine results.

That second channel is the one companies underestimate. A licence holder that passed verification years ago is not exempt; the next supervision inspection applies the same new scale. Contract manufacturers sit inside the same perimeter, because the rules attach to the production activity rather than to the brand on the label, and a customer audit does not substitute for the regulator’s.

For a foreign group, the exposure sits in Chinese plants making these four families, whether wholly owned or in a joint venture. A plant outside them is untouched by the four principles but still bound by the GMP itself.

What the three grades do

The notice states that items are graded into critical, major and general according to each clause’s importance in the quality system and the risk created when it is not met. The grading is a risk statement rather than a scoring system: it tells an inspector which findings can be tolerated and which cannot.

One point needs care. Practice treats a failed critical item as a failed inspection. That is the settled approach in GMP inspection, not a sentence in these four documents, and it should be attributed to practice rather than to the notice.

Preparing for an inspection under the new scale

A supervision inspection that arrives unannounced is the wrong moment to discover that the quality manual still cites a repealed on-site principle. Three artefacts are worth assembling before the inspection rather than during it.

The first is a clause map: for each critical item in the merged checklist, the internal procedure that satisfies it, its version date, and the person accountable. A map that cannot be produced within a day is not finished, because it is the document an inspector will ask for first.

The second is a change log for the two years before the inspection, covering process, supplier and equipment changes in the four families. A sterilisation parameter altered without revalidation reads as an unvalidated process, not as an administrative gap.

The third is the contract manufacturing chain. Where a foreign group uses a Chinese contract manufacturer, the group’s own quality agreement should already allocate responsibility for the merged items; if the agreement predates the merged checklist, it allocates responsibility for a document that no longer exists.

None of this is a legal requirement in the notice. It is the working order in which inspectors tend to ask, and preparing in that order shortens the inspection rather than the requirements.

Where the four lines differ

The four principles share a structure but not a weak point. For sterile devices the recurring failures cluster around cleanroom environment monitoring, sterilisation process validation and sterile barrier packaging validation. For implantable devices the pressure falls on traceability, from raw material to the finished device. For IVD reagents it falls on raw material and calibrator management, where a supplier change can move a result. For customised dentures it falls on the patient model and on material traceability, because each unit is made to an individual.

These are listed by product logic, not by clause number; the documents are the authority on which item sits in which grade.

A practical timetable

  • Complete a gap analysis now, not at renewal; the new scale already applies.
  • Convert the quality manual and any procedure citing the annex, then re-map to the merged items.
  • Run an internal audit using the three-grade logic, so that findings are ranked the way an inspector will rank them.
  • Re-evaluate suppliers whose materials feed a critical item, especially IVD raw and implantable materials.
  • Keep the annual self-inspection for products already licensed, and record it against the new item structure.

What this does not change

This is a production-end instrument. It does not alter registration or filing requirements, does not open a new channel and does not change how a device is cleared for the market. A registered device needs no new filing; what changes is how its factory is inspected.

Teams that read the four principles as a registration document will spend a quarter on the wrong file; teams that track registration only meet the risk on inspection day.

Outlook

Expect inspection reports to cite merged clauses rather than annex paragraphs, and expect internal document maps that still separate the GMP from its annexes to look dated within a year. The substantive requirements have not been rewritten; what changed is where they are written down and how findings are graded.

The practical test of readiness is simple: ask the quality head for the clause behind each critical item. If the answer is a page in an annex that no longer stands alone, the conversion has not been done.

Related reading

  • *Brain-Computer Interface Devices: Registration Pathways* (Article 454) — the registration side for an emerging device category.

Sources

  • 国家药监局·关于印发无菌医疗器械等四个检查指导原则的通知：https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjylqx/20261028170125118.html
  • 国家药品监督管理局：https://www.nmpa.gov.cn/
  • 中国政府网：https://www.gov.cn/
  • 国家市场监督管理总局：https://www.samr.gov.cn/

医疗器械 GMP：四个新检查指导原则如何判定符合性

概述

2026 年 10 月 23 日，国家药监局印发四个检查指导原则，配套新修订的《医疗器械生产质量管理规范》实施。规范自 2026 年 11 月 1 日起施行，四个指导原则同日施行。

四个指导原则分别对应无菌医疗器械、植入性医疗器械、体外诊断试剂和定制式义齿。通知同时废止了原国家食品药品监督管理总局印发的三个现场检查指导原则（食药监械监〔2015〕218 号），以及定制式义齿现场检查指导原则（食药监械监〔2016〕165 号）。废止与施行同日完成，中间没有并行期。

附录为什么被并了进去

编制方法在通知里写得很直白：把规范与相应附录融合衔接，转化形成检查项目。附录不再是放在规范旁边单独对照的文本，而成为检查表的一部分。

这会改变质量团队管理文件的方式。过去把程序文件对应到规范、再把附录当作第二层的体系，现在只剩一层，对应关系需要重建，而不是换个标签。做过一次完整映射的团队会发现，真正的工作量在条款对应，不在文字改写。

谁在被用新尺子量

四类产品：无菌医疗器械、植入性医疗器械、体外诊断试剂、定制式义齿。生产许可核查与上市后监督检查，都按新指导原则进行结果判定。

第二条渠道最容易被低估。多年前通过核查的持证企业并不豁免，下一次监督检查用的就是同一把新尺子。受托生产企业也在同一范围内，因为规则约束的是生产活动，而不是标签上的品牌；客户审核替代不了监管检查。

对外资集团而言，敞口集中在境内生产这四类产品的工厂，无论独资还是合资，也包括为集团产品线供货的本地基地。不生产这四类产品的工厂不受这四个指导原则约束，但仍受规范本身约束。

三个等级起什么作用

通知明确，检查项目按各条款在质量管理体系中的重要性以及不符合所带来的质量安全风险程度，划分为关键项目、主要项目、一般项目三个等级。分级是风险表述，不是打分制度：它告诉检查员哪些缺陷可以容忍，哪些不能。

写给董事会的材料里有一点要留神。实务中，关键项目不合格通常直接判定不通过。这是 GMP 检查的通行做法，不是这四份文件写明的条文，引用时应当归到实务，而不是归到通知。

按新尺子准备一次检查

等监督检查上门那天才发现质量手册还在引用已废止的现场检查指导原则，是最糟糕的时点。有三样东西值得在检查之前备好，而不是在检查当中去找。

第一份是条款对应表：合并后清单上的每一个关键项目，对应哪一份内部程序、版本日期、责任人是谁。一份一天之内拿不出来的对应表等于还没做完，因为这是检查员最先要的文件。

第二份是检查前两年的变更台账，覆盖这四类产品的工艺、供应商与设备变更。灭菌参数改了却没有再确认，在检查里读作”工艺未确认”，而不是”记录不全”。

第三份是受托生产链条。外资集团若使用境内受托生产企业，集团自身的质量协议里就应当已经就合并后的检查项目划分了责任；如果协议签署早于合并清单，它划分的是一份已经不存在的文件上的责任。

这些都不是通知里的法定要求。它们只是检查员通常的问询顺序，按这个顺序准备，缩短的是检查过程，而不是要求本身。

四条线的差别在哪里

四个指导原则结构相同，薄弱点不同。无菌器械的重复性问题集中在洁净区环境监测、灭菌过程确认和无菌屏障包装验证。植入性器械的压力落在可追溯性上，从原材料一直到成品。体外诊断试剂落在原料与校准品管理，供应商一换，结果就可能漂移。定制式义齿落在医患模型与材料溯源，因为每一件都是按个人定制。

这些是按产品逻辑列的，不是按条款号列的。哪一项属于哪个等级，以文件本身为准；把行业经验当成条文引用，是这类文章最常见的错误。

没有改变什么

这是生产端的文件。它不改变注册与备案要求，不新设申请通道，也不改变产品如何获准上市。产品已经注册的企业，不需要为此新交一份申请；改变的是工厂如何被检查。

把四个指导原则当成注册文件来读的团队，会把一个季度花在错误的材料上。反过来，只盯注册进度、不更新体系文件的团队，风险要到检查那天才显现。

一份可执行的时间表

  • 现在就对着四个指导原则做差距分析，不要等到换证；新尺子已经生效。
  • 换版质量手册，以及那些引用了附录的程序文件，再把它们重新对应到合并后的检查项目。
  • 用三个等级的逻辑做一次内审，让自查发现的问题按检查员的方式排序。
  • 对供应关键项目物料的上游做再评价，体外诊断原料与植入材料尤其如此。
  • 对已取证产品继续做年度自查，并按新的项目结构留痕。

展望

可以预期检查报告将引用合并后的条款，而不是附录段落；那些仍把规范与附录分开管理的内部文件地图，一年之内就会显得过时。实质性要求并没有重写，改变的是它们写在哪里、以及缺陷如何分级。

检验准备程度有一个很简单的办法：请质量负责人指出新清单上每一个关键项目背后的条款。如果答案仍然是某一页已经不再单独成立的附录，那么转化工作其实没有做。

延伸阅读

  • 《脑机接口医疗器械：注册路径》（第 454 篇）——新兴器械类别的注册一侧。

来源

  • 国家药监局·关于印发无菌医疗器械等四个检查指导原则的通知：https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjylqx/20261028170125118.html
  • 国家药品监督管理局：https://www.nmpa.gov.cn/
  • 中国政府网：https://www.gov.cn/
  • 国家市场监督管理总局：https://www.samr.gov.cn/